https://scholars.lib.ntu.edu.tw/handle/123456789/515724
標題: | Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan | 作者: | FENG-MING TIEN CHENG-HONG TSAI JIA-HAU LIU Lin C.-T. |
關鍵字: | Brentuximab vedotin; Hodgkin lymphoma; Relapse; Transplantation | 公開日期: | 2019 | 卷: | 118 | 期: | 10 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Hodgkin lymphoma (HL) is a highly curable hematologic malignancy. Relapsed/refractory (R/R) HL is an important clinical challenge, despite advances in treatment. Brentuximab vedotin (BV) is highly effective in R/R HL in the western world. However, there are no real-world data on the use of BV in the Asian population. Our study aimed to evaluate the efficacy and safety of BV as salvage therapy in R/R HL patients in Taiwan. We recruited 20 R/R HL patients who received BV at National Taiwan University Hospital. BV was administered at 1.8 mg/kg once every 3 weeks. The median number of systemic treatment received before BV was three. The overall response rate was 73.7% with a complete remission rate of 21.1% in R/R HL. Overall survival was not reached and progression-free survival was 6.8 months. BV could strengthen disease control before transplantation and improve post-transplant outcomes, even among those heavily pretreated patients, without significant overlapping toxicities with prior therapies. Our data suggest that BV is well tolerated and effective in the treatment of Asian patients with R/R HL. BV may offer long-term disease control in selected patients. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/515724 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.07.003 72245407 |
SDG/關鍵字: | brentuximab vedotin; granulocyte colony stimulating factor; hemoglobin; brentuximab vedotin; immunological antineoplastic agent; adult; aged; allogeneic stem cell transplantation; anemia; Article; Asian; autologous stem cell transplantation; cancer chemotherapy; cancer control; clinical article; clinical outcome; cytopenia; drug efficacy; drug safety; drug tolerability; female; hemoglobin blood level; Hodgkin disease; human; male; monotherapy; multiple cycle treatment; neutropenia; overall survival; peripheral neuropathy; positron emission tomography; progression free survival; relapsed refractory Hodgkin lymphoma; remission; retrospective study; salvage therapy; survival prediction; systemic therapy; Taiwan; treatment response; adolescent; adverse event; Hodgkin disease; middle aged; recurrent disease; retreatment; survival rate; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Brentuximab Vedotin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Progression-Free Survival; Recurrence; Retreatment; Salvage Therapy; Survival Rate; Taiwan; Young Adult |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。